Phase 2 N=289 Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site
Carcinoma
Primary: Overall Survival — 13.43; 7.62 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=60 Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Carcinoma of Unknown Primary Site
Neoplasm, Unknown Primary
Primary: Overall Survival (OS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Death — 12.6 months
Phase 3 N=198 Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site
Neoplasms, Unknown Primary
Primary: Overall Survival (OS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Death — 7.4; 8.5 months
Phase 2 N=46 Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
Carcinoma of Unknown Primary Origin
Primary: Percentage of Participants With Confirmed Tumor Responses — 36 percentage of participants
Phase 2 N=35 Trial of Pembrolizumab in Cancer of Unknown Primary
Cancer of Unknown Primary Site
Primary: Overall Response Rate (ORR) by RECIST Criteria v1.1 in the Second-line & First-line Setting. — 0; 4; 9; 13 Participants
Phase 2 N=48 Oxaliplatin and Capecitabine in the Treatment of Relapsed/Refractory Carcinoma of Unknown Primary Site
Neoplasms, Unknown Primary
Primary: Progression Free Survival — 3.7 months
Phase 2 N=31 Gemcitabine and Irinotecan in Treating Patients With Cancer of Unknown Primary
Carcinoma of Unknown Primary
Primary: Confirmed Response Rate (Partial or Complete Response for 2 Consecutive Evaluations at Least 4 Weeks Apart) as Measured by RECIST Criteria — 9; 13 percentage of patients…
Phase 2 N=529 A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site
Cancer of Unknown Primary Site
Primary: Progression Free Survival (PFS) as Assessed by the Investigator According to Response Evaluation Criteria In Solid Tumors v1.1 (RECIST v1.1) — 6.14; 4.40 Months — p=0.0177
Phase 2 N=10 Sintilimab in Cancer of Unknown Primary
Cancer of Unknown Primary Site
Primary: Confirmed Objective Response Rate (cORR) by RECISTv1.1 — 40 percentage of participants
Phase 2 N=89 Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary
Carcinoma of Unknown Primary
Primary: Progression Free Survival — 5.4; 5.3 months
Phase 2 N=36 Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas
High Grade Malignant Neuroendocrine Carcinoma (Diagnosis)
Primary: Overall Response Rate (ORR) — 7; 5 percentage of participants
Phase 2 N=123 Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin
Neuroendocrine Tumors · Neuroendocrine Neoplasm of Lung
Primary: Clinical Benefit Rate (CBR) — 0; 0; 0; 1 Participants
Phase 2 N=37 Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.
Neuroendocrine Tumors · Neuroendocrine Neoplasm · Gastroenteropancreatic Neuroendocrine Tumor
Primary: Overall Survival Rate at 12 Months — 54.1 % of participants
N/A N=90 Primary Operation in SYnchronous meTastasized InVasivE Breast Cancer
Synchronous Metastasized Breast Cancer · Circulating Tumor Cells
Primary: Overall Survival (OS) — 34.6; 56.2 months — p=0.042
Phase 2 N=20 S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
Sarcoma
Primary: Patients With Response (Confirmed Complete, and Partial) With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor When Treated With Erlotinib. — 0…
Phase 2 N=75 Priming Immunotherapy in Advanced Disease With Radiation
Non-small Cell Lung Cancer · Squamous Cell Carcinoma of the Head and Neck
Primary: Proportion of Participants Alive and Without Progression — .66 proportion of participants
Phase 2 N=27 Pembrolizumab TX-naive Distant Mets Melanoma and Use of (C11-AMT) PET at Baseline as Imaging Biomarker
Melanoma
Primary: Association of Baseline C11-AMT PET SUV Max Value With Objective Response — 6; 6; 1; 13 Participants — p=0.08
Phase 2 N=13 Antineoplaston Therapy in Treating Children With Primitive Neuroectodermal Tumors
Childhood CNS Primitive Neuroectodermal Tumor
Primary: Number of Participants With Objective Response — 3; 1; 1; 7 Participants
Phase 2 N=14 A Study of BKM120 (Buparlisib) in Relapsed or Refractory Thymomas
Thymoma
Primary: Percent of Patients With Objective Response — 7.1 percentage of participants
Phase 2 N=20 Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma
Metastatic Leiomyosarcoma · Unresectable Leiomyosarcoma · Uterine Corpus Leiomyosarcoma
Primary: Objective Response Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 Among Patients With Advanced Leiomyosarcoma of the Uterus (ULMS) Treated With Nivolumab…
Phase 2 N=30 Neoadjuvant Pembrolizumab
Non-small Cell Lung Carcinoma
Primary: Surgical Feasibility Rate as Measured by the Number of Subjects Who Undergo Surgery Following Neoadjuvant Pembrozulimab — 24 Participants
Phase 2 N=116 Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)
Well-differentiated Non-functional NET of Thoracic Origin · Well-differentiated Non-functional NET of Gastrointestinal Origin · Well-differentiated Non-functional NET of Pancreatic Origin
Primary: Overall Response Rate (ORR) by RECIST 1.1 and as Per Blinded Independent Central Review (BIRC). — 7.4; 4.8 Percentage of participants
Phase 2 N=40 Antineoplaston Therapy in Treating Patients With Primary Malignant Brain Tumors
Malignant Brain Tumors
Primary: Number of Participants With Objective Response — 2; 2; 4; 19 Participants
Phase 2 N=140 Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours
Advanced Rare Tumours
Primary: Objective Response Rate Measured by RECIST Version 1.1 — 1; 19; 32; 76 Participants
Phase 2 N=80 PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression
Adenocarcinoma
Primary: Overall Survival — 15.7; 9.0 months — p=0.0024
N/A N=26 Immunotherapy of the Paraneoplastic Syndromes
Paraneoplastic Syndromes
Primary: Survival of Patients With Paraneoplastic Disease Who Are Treated With Tacrolimus — 48 months
Phase 2 N=64 Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer
Advanced Melanoma · Triple-Negative Breast Cancer
Primary: The Primary Efficacy Endpoint Was ORR, Defined as the Proportion of Subjects Demonstrating CR or PR Based on RECIST v1.1 Criteria. — 1; 1; 0; 5 Participants
N/A N=2 Next Generation Sequencing-Based Stratification of Front Line Treatment of HighGrade Neuroendocrine Carcinoma
Large-Cell Neuroendocrine Carcinoma
Primary: Sequencing Rate (Feasibility)
Phase 2 N=341 Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors
Neuroendocrine Tumors · Von Hippel-Lindau Syndrome · Hippel-Lindau Disease
Primary: Number of Lesions Detected Using the 68Gallium-DOTATATE Positron Emission Tomography (PET/Computed Tomography (CT)) Scan — 847 Number of lesions
Phase 2 N=12 Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes
Anti-p53 TCR-Gene
Primary: Clinical Tumor Regression — 1 Participants